Edgemond James, serving as CFO and Treasurer, has been a consistent seller of United Therapeutics Corporation (UTHR) stock, with a transaction history that shows no open-market purchases whatsoever. Across 415 total filings, James has disposed of shares worth approximately $209.6 million, a figure that dwarfs any acquisition activity. The most recent cluster of trades, all occurring in June 2026, reinforces this pattern: 23 sales were recorded against zero buys, with the largest individual transactions taking place on June 22. On that date alone, James executed eight separate sales totaling roughly $4.5 million, including a single block valued at $1.22 million, alongside an option exercise worth $1.28 million that was immediately followed by the share disposals.
The June 18 filings tell a similar story, with 14 sales ranging from $21,741 to $1.61 million, aggregating to approximately $5.5 million in proceeds, paired with a $1.46 million option exercise. The June 15 trades added another $761,461 in sales. While the option exercises (coded "M") are mechanical events that provide the shares, the subsequent open-market sales (coded "S") represent the only discretionary action in the filings. The absence of any "P" coded purchases—the only transaction type that signals conviction buying—combined with the sheer volume of sales, paints a clear directional picture: James has been a net and consistent seller of UTHR stock throughout the period covered by these filings, with no indication of accumulation or a shift toward a buying stance.
AI-assisted summary